Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Viva Wine Group AB in connection with the acquisition of the Norwegian beverage company Alpha Brands
Mandate

Vinge has advised Viva Wine Group AB in connection with the acquisition of the Norwegian beverage company Alpha Brands

February 09, 2026 M&A

Vinge has advised Viva Wine Group AB in connection with the acquisition of 60 percent of the shares in the Norwegian beverage company Alpha Brands, for an initial cash purchase price of MNOK 33, with a possible earn-out based on the company's performance development.

Alpha Brands is a Norwegian company selling beverages to grocery stores in the “NoLo” category, i.e., non-alcoholic and low-alcohol beverages. With the acquisition of Alpha Brands, Viva Wine Group strengthens its position in both the Norwegian market and within this growing category.

Vinge’s team consisted of Anna Jonsson, Michaela Ådén, Lisa Bourghardt, Hedvig Josefson, Tilda Hall and Tove Hallbäck.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026